Blood Cancer Diagnostics Market Size, Share & Trends Analysis Report By Test Type (Blood tests., Biopsy, Imaging tests, Molecular tests), By Product (Instruments, Assay kits & reagents), By End-User (Hospitals, Specialty clinics, Diagnostic Centers, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2025-2033

Blood Cancer Diagnostics Market Size

The global blood cancer diagnostics market size was valued at USD 11.57 billion in 2024 and is projected to grow from USD 12.32 billion in 2025 to reach USD 18.27 billion by 2033, exhibiting a CAGR of 5.1% during the forecast period (2025-2033).

Blood cancer diagnostics encompass a variety of medical tests and procedures used to detect and identify cancers affecting the blood, including leukemia, lymphoma, and myeloma. These cancers typically originate in the bone marrow or lymphatic system, disrupting the normal production of blood cells. Common diagnostic methods include blood tests, such as a CBC, bone marrow biopsies, imaging techniques like CT scans and MRIs, and molecular genetic tests that detect DNA abnormalities in blood cells. Early and accurate detection is essential for effective treatment, as blood cancers often progress rapidly if left untreated.

The global blood cancer diagnostics market is experiencing rapid growth, driven by an increasing number of diagnoses and advancements in diagnostic technologies. The integration of cutting-edge technologies like AI, machine learning, deep learning, next-generation sequencing, and non-invasive sampling is enhancing the accuracy and speed of diagnosis. These innovations are improving early detection and treatment planning, leading to higher survival rates among patients and further propelling market growth.

The pie chart below shows the estimation of new cases of various types of blood cancers in the U.S. in 2024

Source: Straits Research, The Leukemia & Lymphoma Society (LLS)

According to recent data, the three major types of blood cancer—leukemia, lymphoma, and myeloma—affect the blood, bone marrow, and lymphatic system, with lymphoma accounting for the highest percentage of cases in the U.S. in 2024. Government initiatives, funding, and awareness programs are vital drivers of the market's growth, helping to increase early detection and improve patient outcomes. Moreover, the growing demand for advanced diagnostic tests presents opportunities for major manufacturers to enhance their offerings and strengthen their presence in the blood cancer diagnostics industry.

Blood Cancer Diagnostics Market Trends

Shift towards advanced diagnostic technologies

The shift towards advanced technologies, such as nanotechnology, is revolutionizing blood cancer diagnostics, particularly in the detection of leukemia. These technologies significantly enhance the sensitivity and precision of diagnostic instruments, enabling the early identification of cancer markers. Innovations in nanotechnology are expected to drive demand for more sophisticated diagnostic equipment and reagents.

• For example, in October 2024, an article titled "Advancements in Leukemia Management: Bridging Diagnosis, Prognosis, and Nanotechnology" highlighted how nanotechnology is improving leukemia diagnosis. This technological integration is poised to accelerate growth in the blood cancer diagnostic market.

Integration of AI and machine learning in blood cancer diagnosis

Artificial Intelligence and machine learning (ML) are becoming essential tools in blood cancer research, particularly for early detection. These technologies enable more accurate identification of hematologic cancers, which is crucial for timely intervention.

• For instance, in January 2025, a team from the University of Oxford developed TriOx, a liquid biopsy test powered by AI and sophisticated DNA analysis capable of detecting six types of cancer at early stages. The test demonstrated remarkable sensitivity and specificity, offering a minimally invasive option for early detection.

The integration of AI and machine learning into blood cancer diagnostics is set to drive further growth in the market by enhancing early detection and improving diagnostic accuracy.

Market Growth Factors

Technological advancement

Technological advancements, particularly in next-generation sequencing and molecular testing, are driving the growth of the blood cancer diagnostic market. NGS allows physicians to visualize the entire genome of cancer cells, enabling the detection of specific genetic mutations, while molecular testing identifies changes in genetic material that can signal the presence of early-stage tumors. These innovations significantly enhance the accuracy and speed of diagnostics, facilitating early detection and proactive care.

• For example, in September 2023, Dr. Wesam Ahmed, Chair of Hematology and Medical Oncology at Cleveland Clinic Abu Dhabi, highlighted how advancements in precision oncology, such as NGS and molecular testing, provide more precise diagnostics and personalized treatment for blood cancers.

By leveraging these advanced technologies, the market can offer more accurate and timely blood cancer diagnoses, leading to better patient outcomes.

Government initiatives and awareness

Government initiatives are crucial to propel the blood cancer diagnostic market by funding research on early detection and cutting-edge diagnostic technologies. These programs help to develop minimally invasive diagnostics by fostering advancements in cancer genomics, AI, and ML, thereby improving early diagnosis and treatment outcomes. This proactive approach enhances access to advanced diagnostics, further boosting market growth.

• In October 2024, IIT Bombay and Tata Memorial Center India made significant progress in CAR T-cell therapy for blood cancers such as Acute Lymphoblastic Leukemia (B-ALL) and Non-Hodgkin Lymphoma (B-NHL), backed by government grants and approvals from the Drug Controller General of India (DCGI).

Such initiatives and collaborative efforts taken by the government in India are driving advancements in blood cancer diagnostics, significantly boosting market growth.

Market Restraining Factors

Barriers in accessing cancer diagnostics

One of the significant barriers in the global market for blood cancer diagnostics is the high cost of diagnosis and treatment. Advanced diagnostic technologies such as next-generation sequencing and molecular diagnostics are often beyond the financial reach of many patients in these regions. As a result, individuals may delay or forgo essential diagnostic and therapeutic interventions, exacerbating the strain on healthcare systems and leading to poorer outcomes.

Moreover, the limited accessibility to these advanced technologies prevents their widespread adoption and hinders overall market growth. Therefore, financial constraints significantly impede the global expansion and equitable distribution of blood cancer diagnostic solutions, highlighting the need for more affordable options.

Blood Cancer Diagnostics Market Opportunities

Partnership and collaboration between various research institutes

Partnerships between biotech companies, research organizations, and healthcare providers present significant opportunities in the blood cancer diagnostic market. These collaborations can accelerate the development of advanced diagnostic technologies, enabling earlier, more precise detection of blood cancers and addressing unmet clinical needs.

• For example, in October 2024, the Dana-Farber Cancer Institute, in partnership with Johns Hopkins and Brigham and Women's Hospital, engineered a CRISPR-based, point-of-care molecular diagnostic for acute promyelocytic leukemia and chronic myeloid leukemia.

By bridging research and clinical practice, such collaborations make cutting-edge diagnostics more accessible. These efforts contribute to innovations in blood cancer diagnostics, expanding market opportunities and improving patient outcomes.

Regional Insights

North America: Dominant region with 39.7% market share

North America leads the global blood cancer diagnostics market, driven by access to advanced technologies, robust healthcare infrastructure, and a high prevalence of blood cancer. The region benefits from significant funding and support from both government and private sectors, alongside numerous initiatives and awareness programs.

Moreover, the increasing number of research and development studies, along with technological advancements in diagnostic techniques, is propelling market growth. The region's growing emphasis on cost-effective healthcare solutions further accelerates the expansion of the blood cancer diagnostic market.

Asia Pacific: Fastest growing region with the highest market CAGR

Asia-Pacific is expected to register the fastest CAGR during the forecast period. This is attributed to factors such as the increasing need for infrastructure, technologies, diagnostic tests for cancer treatment, and a large population with growing healthcare needs. Moreover, the region benefits from improving infrastructure, government initiatives promoting cancer awareness, and a growing demand for affordable cancer diagnostic tests and services.

Country Insights

• U.S.– The U.S. leads the global market, driven by advanced healthcare infrastructure, significant research investments, and a high prevalence of leukemia, lymphoma, and myeloma. In May 2024, reports estimated that these cancers would account for 9.4% of new cancer cases in the U.S. The demand for early detection and precise diagnostics fuels market growth, with innovations like next-generation sequencing and liquid biopsy enhancing diagnostic accuracy and patient outcomes.
• Germany– Germany stands out in Europe's market due to its emphasis on healthcare innovation, widespread use of advanced diagnostic methods like flow cytometry and genetic testing, and strong government-backed research funding. The country’s commitment to precision medicine and early cancer detection accelerates market share. With initiatives promoting AI-driven diagnostics and biomarker-based testing, Germany continues to set benchmarks for cutting-edge cancer research and diagnostic advancements.
• China – China’s vast population and expanding healthcare infrastructure drive demand for advanced blood cancer diagnostics. Research institutions are developing AI-powered tools for early cancer detection, such as Shanghai Jiao Tong University’s July 2024 innovation, which diagnoses cancer from a single drop of dried blood using nanoparticle-enhanced mass spectrometry. These advancements aim to improve early-stage detection, particularly in rural regions, positioning China as a leader in integrating AI and molecular diagnostics for cancer screening.
• France– France’s strong healthcare system and research-driven approach fuel growth in the market. The country prioritizes innovation, with programs like the November 2024 LEUKEMIA 360 event in Paris, bringing together industry experts, academics, and healthcare professionals to advance leukemia research. This event promotes collaboration and accelerates the development of novel diagnostic solutions, enhancing early detection and personalized treatment strategies for blood cancer patients across the country.
• India – India's rapidly growing blood cancer diagnostics industry is driven by rising cancer incidence, expanding healthcare access, and government initiatives. Programs like the DHR-ICMR Advanced Molecular Oncology Diagnostic Services, launched in January 2023, provide advanced molecular diagnostic services across government medical colleges, improving access to early detection. Moreover, increased awareness campaigns and investment in cutting-edge technologies like liquid biopsy and AI-powered genetic testing further strengthen India’s role.
• Saudi Arabia – Saudi Arabia’s market benefits from government-backed initiatives and investments in molecular testing and imaging technologies. In January 2024, QIAGEN expanded its presence in the Middle East by opening a regional headquarters in Riyadh, fostering collaboration in precision diagnostics. The country’s focus on advanced healthcare infrastructure, combined with AI-driven diagnostic tools, enhances early detection capabilities and reinforces Saudi Arabia’s position as a key player in the Middle Eastern diagnostics market.

Segmentation Analysis

The global blood cancer diagnostics market is segmented into test type, product type, and end-user.

By Test Type

The blood test segment leads the market due to its high accuracy and essential role in early detection. Blood tests, such as multi-cancer early detection (MCED) tests, offer improved sensitivity by combining molecular analysis of liquid biopsies with AI, enabling better differentiation of tumor types. For example, in March 2023, these tests were shown to lower cancer mortality by detecting cancers at earlier stages, highlighting their importance in precision diagnosis and early intervention.

By Product

The instruments segment holds the largest market share in blood cancer diagnostics, driven by the demand for advanced, accurate, and rapid diagnostic results. Instruments like PCR, flow cytometry, and next-generation sequencing (NGS) are essential for detecting biomarkers or genetic changes linked to blood cancers such as leukemia, lymphoma, and myeloma. These technologies enhance early detection, improve diagnosis accuracy, and play a pivotal role in the market's revenue growth.

By End-User

Hospitals dominate the blood cancer diagnostic market, holding the largest share due to their provision of advanced diagnostic methods, timely results, and comprehensive care. Hospitals offer services like personalized medicine, state-of-the-art diagnostic tools, and emergency treatment, which are crucial for effective blood cancer diagnosis and management. With their ability to provide immediate and accurate results, hospitals remain central to the market’s growth, offering both diagnostic solutions and post-diagnosis care for patients.

Company Market Share

Key players in the industry are focusing on adopting key business strategies such as strategic collaborations, product approvals, acquisitions, and product launches to gain a strong foothold in the market. Companies are investing in research and development to enhance diagnostic accuracy and efficiency, integrating AI and molecular diagnostics for early cancer detection.

Guardant Health: An emerging player in global blood cancer diagnostics market

Guardant Health, founded in 2012, is a pioneer precision medicine company dedicated to maintaining wellness and securing more cancer-free years for patients. The company revolutionizes cancer diagnostics by leveraging cutting-edge technologies, including next-generation sequencing (NGS), liquid biopsies, and AI-driven analytics. Guardant Health’s comprehensive testing solutions analyze blood, tissues, and real-world data to detect cancer at its earliest stages, guide treatment decisions, and monitor disease progression.

Recent developments by Guardant Health:

• In June 2024, Guardant Health launched an updated version of its Guardant360 TissueNext test. This improved Medicare-covered test allows oncologists to have a more streamlined workflow and get results faster, helping them make the most accurate blood cancer diagnostics treatment decisions.

Recent Developments

• January 2025 –Immuneel Therapeutics introduced Qartemi, India’s second CAR-T cell therapy, targeting B-cell Non-Hodgkin Lymphoma. This breakthrough therapy harnesses genetically modified T-cells to destroy cancer cells, significantly improving treatment outcomes. Qartemi is offered at a fraction of the cost of similar therapies in Western countries, making it more accessible to a broader patient base.
• April 2024 – QIAGEN announced plans to introduce its QIAcuityDx system, a real-time PCR system for in vitro diagnostic testing, by the end of the year. Using this digital PCR technology, laboratories can produce and perform IVD assays or lab-developed tests (LDTs) to provide same-day results. This system aims to enhance the precision and speed of molecular diagnostics, including the detection of blood cancers.

Analyst Opinion

As per our analysts, the global market for blood cancer diagnostics is set for significant growth, driven by rapid technological advancements, AI integration, and increasing government funding and initiatives. Cutting-edge technologies such as next-generation sequencing (NGS), machine learning, deep learning, and molecular testing are revolutionizing early detection and precision diagnostics.

Moreover, the rising prevalence of blood cancers like leukemia, lymphoma, and myeloma is fueling the demand for advanced diagnostic solutions. Emerging economies, particularly in the Asia-Pacific region, present untapped opportunities due to expanding healthcare infrastructure and a growing population with increasing healthcare needs.

Despite these opportunities, the market faces challenges such as high costs of advanced diagnostic tests, disparities in access to cutting-edge technologies, and regulatory hurdles. However, ongoing research, collaborations, and government support continue to mitigate these barriers, ensuring long-term market expansion.